Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

09. Dezember 2015 17:30 ET | Quelle: MediciNova, Inc.

MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder (AUD) Reported at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting

LA JOLLA, Calif., Dec. 09, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock...
06. Dezember 2015 18:00 ET | Quelle: MediciNova, Inc.

MediciNova Announces Presentation Regarding Clinical Trial of MN-166 (ibudilast) in ALS at the 6th Annual California ALS Pac10 and Research Network Meeting at UCSD, La Jolla, California　

LA JOLLA, Calif., Dec. 06, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
19. November 2015 06:00 ET | Quelle: MediciNova, Inc.

MediciNova to Initiate Clinical Trial Evaluating MN-001 in NASH Patients With Hypertriglyceridemia

LA JOLLA, Calif., Nov. 19, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
10. November 2015 18:00 ET | Quelle: MediciNova, Inc.

MediciNova Receives Notice of Allowance for New Patent Covering MN-221 (bedoradrine) for the Treatment of Irritable Bowel Syndrome in Japan

LA JOLLA, Calif., Nov. 10, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
09. November 2015 18:00 ET | Quelle: MediciNova, Inc.

FDA Approves a New Clinical Protocol to Evaluate the Effects of MN-166 (ibudilast) on a Biomarker of ALS; MediciNova Plans to Initiate a Clinical Trial with MGH (Massachusetts General Hospital)

LA JOLLA, Calif., Nov. 09, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
04. November 2015 06:00 ET | Quelle: MediciNova, Inc.

MediciNova Announces Interim Data From Clinical Trial of MN-166 (ibudilast) in ALS to be Presented at the 14th Annual NEALS (Northeast Amyotrophic Lateral Sclerosis) Meeting in Clearwater Beach, Florida

LA JOLLA, Calif., Nov. 04, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
13. Oktober 2015 19:00 ET | Quelle: MediciNova, Inc.

MediciNova to Present Preclinical Data on MN-166 (ibudilast) at the 26th International Symposium on ALS/MND in Orlando, FL

LA JOLLA, Calif., Oct. 13, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
09. Oktober 2015 06:00 ET | Quelle: MediciNova, Inc.

MediciNova to Initiate Clinical Trial of MN-001 (tipelukast) in IPF

LA JOLLA, Calif., Oct. 09, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
24. September 2015 06:00 ET | Quelle: MediciNova, Inc.

MediciNova to Present at the Ladenburg Thalmann 2015 Healthcare Conference

LA JOLLA, Calif., Sept. 24, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
10. September 2015 06:00 ET | Quelle: MediciNova, Inc.

FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of Idiopathic Pulmonary Fibrosis

LA JOLLA, Calif., Sept. 10, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...

Vorherige Seite

Nächste Seite